Citations

Clear

175 citation(s) found for "Santa-Maria, C".

Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ ‐1 Study Eligibility: A Large Global Analysis in a Real‐World Setting
Prinzi, Federica Lo , Rimini, Margherita , Ikeda, Masafumi, Antonuzzo, Lorenzo, Kim, Jin Won, Pressiani, Tiziana, Peeters, Frederik , Pinato, David J., Pircher, Chiara, Tamberi, Stefano, Couto, Nuno, Chon, Hong Jae, Martirena, A. , Lamarca, Angela, Perkhofer, Lukas , Kim, Il Hwan, Pinto, C. , Kang, Beodeul, Pastorino, Alessandro , Changhoon, Yoo, Rodriquenz, Maria Grazia , Scartozzi, Mario, Zumstein, Lucrezia , Ghidini, Michele, Aprile, Giuseppe , Spinelli, Gian Paolo , Yung‐Yeh, Su, Warmington, Emily , Lancianese, Alessia , Satake, Tomoyuki, Bekaii‐Saab, Tanios, Lavacchi, Daniele, Passeri, Laura , Kang, Minsu, Prete, Alessandra Anna, Bozzarelli, Silvia, Persano, Mara , Masi, Gianluca, Balsano, Rita , Lonardi, Sara, Salani, Francesca, Camera, Silvia, Vogel, Arndt, Rimassa, Lorenza, Rimassa, Lorenza , Vivaldi, Caterina , Farinea, Giovanni , Prager, Gerald W , Chan, Stephen L , Niger, Monica , Fornaro, Lorenzo , Casadei-Gardini, Andrea , Lo Prinzi, Federica , Rimassa, Lorenza , Saborowski, Anna , Rimini, Margherita , Ikeda, Masafumi , Abidoye, Oluseyi , Lucchetti, Jessica , Antonuzzo, Lorenzo , Kim, Jin Won , Nichetti, Federico , Pressiani, Tiziana , Vivaldi, Caterina , Rapposelli, Ilario Giovanni , Braconi, Chiara , Pinato, David J. , Tamburini, Emiliano , Pircher, Chiara , Tamberi, Stefano , Castet, Florian , Verrico, Monica , Parisi, Alessandro , Couto, Nuno, Chon, Hong Jae , Lamarca, Angela , Landriscina, Matteo , Finkelmeier, Fabian , Oneda, Ester , Avallone, Antonio , Dell’Aquila, Emanuela , Kim, Il Hwan, Formica, Vincenzo , Garajova, Ingrid , Kang, Beodeul , Corallo, Salvatore , Fenocchio, Elisabetta , Diana, Anna , Schirripa, Marta , Scartozzi, Mario , Ghidini, Michele , Prager, Gerald W. , Chan, Stephen L. , Warmington, Emily, Satake, Tomoyuki , Bekaii‐Saab, Tanios , Giordano, Guido , Ferrara, Michele , Kang, Minsu, Prete, Alessandra Anna , Bozzarelli, Silvia , Masi, Gianluca , Niger, Monica , Lonardi, Sara , Salani, Francesca , Camera, Silvia , Vogel, Arndt , Fornaro, Lorenzo , Casadei‐Gardini, Andrea

Mayo Clinic

International Journal of Cancer | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ijc.70699 | PMID 42581755 Get It

ABSTRACT Many real‐world patients with advanced biliary tract cancer (BTC) are excluded by TOPAZ‐1 criteria; this study assessed cisplatin and gemcitabine plus durvalumab (CGD) efficacy and safety in these patients. Data from 1358 patients with advanced BTC treated with first‐line CGD across 55 international centers were retrospectively analyzed. Patients were classified as TOPAZ‐1‐in (meeting all inclusion criteria) or TOPAZ‐1‐out (meeting ≥ 1 exclusion criterion). Primary endpoints were overall survival (OS) and progression‐free survival (PFS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and safety. Furthermore, OS and PFS of the TOPAZ‐1‐out cohort were compared with reconstructed survival data from the phase III trial. 912 (67.1%) patients were classified as TOPAZ‐1‐in , and 446 (32.9%) as TOPAZ‐1‐out . After a median follow‐up of 14.5 months (95% CI: 13.7–36.5), OS was 16.1 months in TOPAZ‐1‐in and 12.5 months in TOPAZ‐1‐out (HR 0.69, 95% CI: 14.6–16.5, p = 0.0001); PFS was 8.2 versus 6.5 months (HR 0.73, 95% CI: 7.1–8.1, p < 0.0001). Median OS in the TOPAZ‐1‐out cohort (12.5 months) was nearly identical to the phase III trial experimental arm (12.9 months; HR 1.15, p = 0.13); for PFS the HR was 1.12 (95% CI 0.93–1.42; p = 0.09). Among TOPAZ‐1‐out patients, active infection, elevated bilirubin, and ECOG PS > 1 were linked to poorer OS, while no detrimental impact emerged for ALT/AST abnormalities, corticosteroid use, renal or hematologic parameters, or prior surgery within 6 months, suggesting treatment effectiveness was broadly maintained across clinical subgroups. Furthermore, TOPAZ‐1‐out patients experienced no significant increase in adverse events compared with the TOPAZ‐1‐in group. Real‐world data suggest CGD may be effective in TOPAZ‐1‐out patients, with no evident increase in toxicity, supporting the potential expanded use of the regimen in clinical practice.
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real‐World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab
Rimini, Margherita , Lamarca, Angela, Ikeda, Masafumi, Kim, Jin Won , Vogel, Arndt, Peeters, Frederik , Pinato, David J., Pircher, Chiara, Martirena, A. , Perkhofer, Lukas , Pinto, C. , Kang, Beodeul, Pastorino, Alessandro , Changhoon, Yoo, Rodriquenz, Maria Grazia , Scartozzi, Mario, Zumstein, Lucrezia , Ghidini, Michele, Aprile, Giuseppe , Spinelli, Gian Paolo , Yung‐Yeh, Su, Bolnykh, Iakov, Lancianese, Alessia , Satake, Tomoyuki, Lavacchi, Daniele, Passeri, Laura , Kang, Minsu, Viola, Massimo, Persano, Mara , Balsano, Rita , Ratti, Francesca, Rimassa, Lorenza , Kim, Jin Won , Vivaldi, Caterina , Formica, Vincenzo , Farinea, Giovanni , Prager, Gerald W , Chan, Stephen L , Niger, Monica , Fornaro, Lorenzo , Casadei-Gardini, Andrea , Rimassa, Lorenza , Saborowski, Anna , Rimini, Margherita , Lamarca, Angela , Ikeda, Masafumi , Abidoye, Oluseyi , Lucchetti, Jessica , Antonuzzo, Lorenzo , Vogel, Arndt , Nichetti, Federico , Pressiani, Tiziana , Vivaldi, Caterina , Rapposelli, Ilario Giovanni , Braconi, Chiara , Pinato, David J. , Tamburini, Emiliano , Pircher, Chiara , Tamberi, Stefano , Castet, Florian , Verrico, Monica , Parisi, Alessandro , Couto, Nuno , Chon, Hong Jae , Landriscina, Matteo , Finkelmeier, Fabian , Oneda, Ester , Avallone, Antonio , Dell’Aquila, Emanuela , Kim, Il Hwan , Garajova, Ingrid , Kang, Beodeul , Corallo, Salvatore , Fenocchio, Elisabetta , Diana, Anna , Schirripa, Marta , Scartozzi, Mario , Ghidini, Michele , Prager, Gerald W. , Chan, Stephen L. , Bekaii‐Saab, Tanios , Ferrara, Michele , Kang, Minsu, Bozzarelli, Silvia , Masi, Gianluca , Niger, Monica , Lonardi, Sara , Salani, Francesca , Camera, Silvia , Ratti, Francesca , Fornaro, Lorenzo , Casadei‐Gardini, Andrea

Mayo Clinic

International Journal of Cancer | July 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ijc.70641 | PMID 42524843 Get It

ABSTRACT Surgery after response to first‐line chemoimmunotherapy may offer a potential curative option for patients with locally advanced biliary tract cancer (BTC) initially considered unresectable. However, robust real‐world evidence in this setting remains limited. We retrospectively analyzed patients with locally advanced BTC treated with first‐line cisplatin, gemcitabine, and durvalumab (CGD) across 55 centers in 12 countries. Endpoints included overall survival (OS), progression‐free survival (PFS), disease‐free survival (DFS) among resected patients, objective response rate (ORR), and the prognostic impact of surgery. A multivariable logistic regression model was developed to predict surgical conversion using baseline clinical and laboratory variables. Among 1358 screened patients, 219 had locally advanced disease and were included in the analysis. Median follow‐up was 14.5 months. ORR was 34.6%, with median PFS and OS of 10.0 and 20.7 months, respectively. Twenty‐four patients (10.9%) underwent surgical resection after systemic therapy. Median OS was 22.5 months in resected patients versus 19.9 months in those who did not undergo surgery. Median DFS after resection was 15.8 months. Pathological lymph node involvement was independently associated with shorter DFS. Larger baseline tumor size correlated with higher odds of radiological response but not with OS. An exploratory elastic‐net model retained four baseline variables and showed moderate discriminative ability for surgical conversion, with an apparent AUC of 0.72 and an optimism‐corrected AUC of 0.65. First‐line CGD enabled secondary resection in approximately 11% of patients with locally advanced BTC. A simple baseline model may support patient selection for conversion surgery, although prospective validation is needed.
Flow Cytometric Antigen-Specific Immune Responses in Latent Tuberculosis Infection: A Comparison Between Low- and High-Endemic TB Settings 2260608
Escalante, Patricio, Luis, Gutierrez, Sánchez, Pedro Arias, Mercado, Ariana, Reddy, Manik, Piekert, Tobias, Bailey, Ryan, Laniado-Laborin, Rafael, Escalante, Patricio , Pathakumari, Balaji , Sanchez, Pedro Arias, Reddy, Manik R., Bailey, Ryan C , Laniado-Laborin, Rafael

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.948 Get It

Abstract Introduction Screening individuals with latent tuberculosis infection (LTBI) from regions with varying TB endemicity is critical for global TB control. Immune responses to TB differ due to variations in exposure, immune adaptations, and environmental factors. This study evaluated antigen-specific immune responses in untreated LTBI individuals from low- and high-TB-endemic settings. Methods Peripheral blood mononuclear cells from untreated LTBI individuals from low-endemic (USA) and high-TB-endemic settings (Mexico) were stimulated with PPD, MTB300, ESAT-6/CFP-10 (RD1) peptides, mycobacterial glycopeptidolipids (GPL), and controls. We compare flow cytometric immune responses of T-cell intracellular cytokines and activation markers using non-parametric statistical methods. Results We studied age-matched, untreated LTBI individuals who tested IGRA(+)/TST(+) from low-TB-endemic (n = 18) and 18 healthcare workers from a high-TB-endemic settings. IGRA results showed no statistical differences across groups. The frequency of CD3+CD8+IFN-γ+HLA-DR+ and total CD3+TNF-α+ T cells after RD1 stimulation was significantly higher in the high-TB-endemic group (P &lt; 0.05). Additionally, we observed significant increased frequencies in CD3/CD4+TNF-α+HLA-DR+ and CD8+TNF-α+HLA-DR+ T cells stimulated by GPL in the same group, probably associated with nontuberculous mycobacteria (NTM) exposures. Our findings suggest possible recent TB and NTM exposures in healthcare workers from a high-TB-endemic setting, resulted in increased antigen-specific adaptive TNF-α and IFN-γ producing T cells, which are important for pathogen control and immunity. Conclusion We found significant differences in antigen-specific cell immunity, including HLA-DR activated T-cells, a marker of recent antigen encounter, in individuals from a high-TB-endemic settings. These findings underscore the importance of settings-specific immune biomarkers for improving LTBI diagnostics, clinical management, and vaccination trials. Funding Source National Institute of Allergy and Infectious Diseases at the National Institutes of Health Topic Categories Immune Mechanisms of Human Disease (HUM)
Inflammation in coronary syndromes in clinical practice: a clinical consensus statement of the Association for Acute Cardiovascular Care of the European Society of Cardiology, the European Society of Cardiology Working Group on Myocardial and Pericardial D
Kharlamov, John Alexander, Lenz, Max , Madonna, Rosalinda, Schaubroeck, Hannah, Morosin, Marco , Wojta, Johann , Evans, Paul, Huber, Kurt , Tarkin, Jason, Tsaban, Gal , Roubille, François , Lenz, Max , Wojta, Johann , Kerneis, Mathieu , Lazaros, George , Huber, Kurt , Hassager, Christian , Heymans, Stephane , Tsaban, Gal , Imazio, Massimo , Sionis, Alessandro , Kharlamov, Alexander , Madonna, Rosalinda , Delmas, Clément , Schaubroeck, Hannah , Vandenbriele, Christophe , Evans, Paul , Hassager, Christian , Tarkin, Jason M. , Heymans, Stéphane , Christodorescu, Ruxandra , Imazio, Massimo , Sionís, Alessandro

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | July 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ehjacc/zuag086 | PMID 42536391 Get It

Abstract Inflammation is a key driver of coronary syndromes across the continuum from chronic coronary syndromes to acute coronary syndromes. It contributes to atherogenesis, plaque destabilization, and ischaemic events and influences myocardial injury, repair, and remodelling. Inflammatory activity is further amplified by metabolic and autoimmune comorbidities such as diabetes, obesity, and connective tissue diseases, with obesity representing a major driver of chronic low-grade inflammation through adipose tissue dysfunction and cytokine activation, while psychosocial stress and environmental exposures including air pollution serve as additional triggers. Genetic variations, including human leucocyte antigen genotypes, modulate individual susceptibility to vascular inflammation and myocardial injury. This expert consensus from the European Society of Cardiology’s Association for Acute CardioVascular Care summarizes the current understanding of inflammation across the full spectrum of coronary syndromes, including underlying mechanisms, relevant biomarkers, and imaging approaches that characterize vascular inflammation, and integrates insights from experimental and clinical studies. Importantly, this document provides explicit consensus-based guidance on when, how, and in whom inflammation should be assessed and treated in routine clinical practice. While the causal association between inflammation and atherosclerotic cardiovascular disease is well established, pharmacological modification of inflammation has produced conflicting evidence. Some agents, such as low-dose colchicine, have demonstrated modest reductions in cardiovascular events, although results across trials have been inconsistent. Other anti-inflammatory therapies have not shown clinical benefit, whereas selective cytokine inhibition with canakinumab has reduced cardiovascular risk at the cost of increased infection rates. The present manuscript also focuses on the evaluation of inflammatory activity in cardiovascular patients in routine clinical practice. It further discusses criteria for patient selection and clinical decision-making regarding the introduction of anti-inflammatory therapy in individuals with established atherosclerotic cardiovascular disease.
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Gradishar, W J, Moran, Meena S. , Abraham, Jame , Abramson, Vandana, Aft, Rebecca, Agnese, Doreen, Allison, Kimberly H., Anderson, Bethany, Bailey, Janet, Burstein, Harold J. , Chen, Nan , Chew, Helen, Dang, Chau, Giordano, Sharon H., Goetz, Matthew P., Jankowitz, Rachel C., Javid, Sara H., Leitch, A. Marilyn, LYONS, JANICE, McCloskey, Susie, McShane, Melissa , Patel, Sameer A. , Rosenberger, Laura H., Santa‐Maria, Cesar A. , Schneider, Bryan P., Smith, Mary Lou , Soliman, Hatem, Speers, Corey, Telli, Melinda L. , Wei, Mei , Wisinski, Kari B., Yellala, Amulya, Schonfeld, Ryan, Telli, Melinda L , Gradishar, William John, Abramson, Vandana G. , Agnese, Doreen Marie , Allison, Kimberly H. , Bailey, Janet E., Chew, Helen K. , Elias, Anthony , Giordano, Sharon H. , Goetz, Matthew P. , Jankowitz, Rachel C. , Javid, Sara H. , Leitch, A. Marilyn , Rosenberger, Laura H. , Rugo, Hope S. , Santa-Maria, Cesar Augusto , Schneider, Bryan P. , Soliman, Hatem, Speers, Corey , Wisinski, Kari B. , Yeung, Kay T. , Young, Jessica S. , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 9, 2026 | Volume: 24 | Issue: 7 | Pages: No page available

10.6004/jnccn.2026.0033 | PMID 42425164 Get It

The NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget’s disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Breast Cancer focuses on the recommendations for the management of recurrent or stage IV (M1) metastatic breast cancer. It summarizes the treatment strategies stratified by tumor biology, including hormone receptor status and HER2 expression, as well as clinical factors such as prior therapy and disease-free interval. Throughout all treatment lines, supportive care, quality of life preservation, toxicity minimization, and clinical trial participation are emphasized as integral components of patient care.
Impact of prior treatment setting on the efficacy of rucaparib vs physician’s choice in BRCA -mutated castration-resistant prostate cancer (mCRPC) in TRITON3.
Sridhar, Srikala S., Fizazi, Karim Olivier, Chowdhury, Simon, Ryan, Charles J. , Alonso-Gordoa, Teresa, Arranz, José Ángel, Birtle, Alison , Byard, Ian, Carrozza, Francesco , Giorgi, Ugo De, Duran, Ignacio, Goeminne, Jean-charles, Goldfischer, Evan R., Despain, Darrin, Craib, Marcia, Lindberg, Henriette , Sridhar, Srikala S , Fizazi, Karim , Bryce, Alan H. , Chowdhury, Simon, Alonso‐Gordoa, Teresa , Giorgi, Ugo De , Durán, Ignacio , Goeminne, Jean‐Charles, Goldfischer, Evan R., Grimm, Marc‐Oliver , Despain, Darrin , Craib, Marcia L.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 5054-5054

10.1200/jco.2026.44.16_suppl.5054 Get It

5054 Background: Rucaparib significantly improved radiographic progression-free survival (rPFS) versus physician’s choice of docetaxel or an androgen-receptor pathway inhibitor (ARPI) (abiraterone or enzalutamide) in men with BRCA mutations who were chemotherapy-naïve in the mCRPC setting and had received one prior ARPI in the phase 3 TRITON3 trial (NCT02975934). This post-hoc analysis evaluated whether the timing of prior ARPI therapy impacted the efficacy of rucaparib. Methods: Patients were randomized 2:1 to rucaparib (600 mg BID) or physician’s choice of docetaxel or ARPI, after progression on 1 prior second-generation ARPI in any setting. The primary endpoint was rPFS. Outcomes were analyzed according to whether patients received the prior ARPI in the metastatic castration sensitive (mCSPC) or castration resistant (mCRPC) setting. Data cutoff was August 25, 2022. Results: Of the 302 BRCA1/2 patients, 68 received prior ARPI in the mCSPC setting (42 rucaparib; 26 physician’s choice) and 234 in the mCRPC setting (159 rucaparib; 75 physician’s choice). Baseline characteristics were generally similar. Prior treatments in the mCSPC and mCRPC groups, respectively, included abiraterone (73.5% vs 53.0%), enzalutamide (29.4% vs 48.3%), and docetaxel (17.6% vs 24.8%). Median rPFS favored rucaparib over physician’s choice in both groups (mCSPC: 13.6 vs 8.2 months; HR 0.60 [95% CI, 0.32–1.15]; mCRPC: 11.2 vs 5.8 months; HR 0.43 [95% CI, 0.30–0.61]). Median OS was similar between treatments in both settings (mCSPC: 23.2 vs 21.7 months; HR 0.81 [95% CI, 0.47–1.41]; mCRPC: 23.2 vs 21.0 months; HR 0.91 [95% CI, 0.66–1.25]). Treatment-related adverse events occurred at comparable rates (89.6% vs 86.1%). Conclusions: Rucaparib demonstrated efficacy in patients with BRCA-mutated mCRPC, regardless of whether prior ARPI was administered in the mCSPC or mCRPC setting. Clinical trial information: NCT02975934 .
A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF
Hernández–Gea, Virginia , Paradis, Valerie , Guindi, Maha , Alves, Venancio A.F. , Aqul, Amal , Cerda, Eira , Murad, Sarwa Darwish , Das, Prasenjit , Giorgio, Angelo Di , Freitas, Luiz A.R. de , Grammatikopoulos, Tassos , Harada, Kenichi , Hernández, Nelia , Kakar, Sanjay , Karpen, Saul J. , Qi, X L, Sakhuja, Puja , Schinoni, Maria Isabel , Saxena, Romil , Shukla, Akash , Verna, Elizabeth C. , Wong, Kerry, Darwish Murad, Sarwa , Di Giorgio, Angelo , de Freitas, Luiz A R , Ibrahim, Samar H , Kakar, Sanjay , Karpen, Saul , Kleiner, David Erwin , Ormeci, Necati , Qi, Xiaolong , Sakhuja, Puja , Schinoni, Maria Isabel , Saxena, Romil , Sayadi, Alexandre , Shukla, Akash , Tiniakos, Dina , Verna, Elizabeth C , Elkrief, Laure , Sempoux, Christine , Heller, Theo , Rautou, Pierre-Emmanuel , Aqul, Amal , Das, Prasenjit , Hernández–Gea, Virginia , Paradis, Valérie , Guindi, Maha M. , Cerda, Eira, Grammatikopoulos, Tassos , Harada, Kenichi , Hernández, Nelia , Ibrahim, Samar H. , Sayadi, Alexandre , Heller, Theo

Mayo Clinic

Hepatology | May 27, 2026 | Volume: 84 | Issue: 2 | Pages: 601-616

10.1097/hep.0000000000001768 | PMID 42191125 Get It

Noncirrhotic portal hypertension has historically been described using heterogeneous and region-specific terminology—such as idiopathic portal hypertension (IPH), noncirrhotic portal fibrosis (NCPF), obliterative portal venopathy, and nodular regenerative hyperplasia—leading to substantial variability in diagnosis, reporting, and international research collaboration. Differences in guideline definitions from major societies (AASLD, EASL, and APASL), together with the presence of characteristic histologic lesions in patients without clinically overt portal hypertension, have further complicated disease classification. To address these challenges, a large, multisociety, international initiative was convened to harmonize nomenclature and diagnostic criteria. Representatives from liver, pathology, and pediatric hepatology societies across the Americas, Europe, and Asia participated in a structured consensus process that included specialized working groups and external Delphi validation. The initiative produced a globally harmonized and implementable diagnostic framework. Consensus was reached that the terms porto-sinusoidal vascular disorder (PSVD) and NCPF may be used interchangeably when identical diagnostic criteria are applied, and that they should be written as PSVD or NCPF . The diagnosis was defined as fundamentally clinicopathological, requiring integrated assessment. Core principles include the need for a high-quality liver biopsy (≥10 mm), mandatory exclusion of cirrhosis, and systematic exclusion of specific alternative conditions. Importantly, the consensus recognizes that PSVD or NCPF may be diagnosed even without clinical portal hypertension and may coexist with other liver diseases, provided cirrhosis is excluded. Standardized major and minor histologic criteria were developed collaboratively by expert pathologists and externally validated. Features of portal hypertension were harmonized into specific and nonspecific categories applicable to routine clinical practice. An integrated diagnostic scoring system incorporating histology, clinical features, associated conditions, and concommitant etiologies was developed and validated using the Delphi method. This consensus provides the first internationally endorsed, unified framework for the diagnosis of PSVD or NCPF. Its global implementation is expected to reduce diagnostic variability, improve comparability across regions, and facilitate the development of robust, internationally harmonized clinical and translational research cohorts.
Hypercontractile phenotype at rest in chronic coronary syndromes predicts impaired functional reserve and increased mortality
Ciampi, Q C Quirino, Cortigiani, Lauro , Zagatina, Angela, Padang, Ratnasari , Kane, Garvan C, Villarraga, Hector R, Arruda‐Olson, Adelaide M. , Kalinina, Elena, Lowenstein, Jorge, Haber, Diego M Lowenstein, Marconi, Sofia, Boshchenko, Alla, Rodriguez-Zanella, Hugo, Wierzbowska-Drabik, Karina, Kasprzak, J D, Merli, Elisa , Djordjevic-Dikic, Ana, Amor, Miguel, Saad, Ariel, Safarova, Ayten, Timofeeva, T. N. , Vazquez, J P, Rigo, Fausto, Nikolic, Aleksandra, Ostojic, M, Kovacevic-Preradovic, Tamara, Cerracchio, Emma, Tripepi, Giovanni Luigi, Yin, Lixue , Villari, B, Pellikka, Patricia A, Picano, Eugenio, Zagatina, A , Ciampi, Quirino , Wierzbowska‐Drabik, Karina , Kasprzak, Jarosław D. , Ciampi, Quirino , Cortigiani, Lauro , Zagatina, Angela , Padang, Ratnasari , Villarraga, Hector R , Ryabova, Tamara , Rodriguez-Zanella, Hugo , Gaibazzi, Nicola , Pepi, Mauro , Wierzbowska-Drabik, Karina , Kasprzak, Jaroslaw D , Wang, Yi , Kane, Garvan C. , Villarraga, Hector R. , Kalinina, Elena , Lowenstein, Jorge , Arbucci, Rosina , Haber, Diego M. Lowenstein, Čelutkienė, Jelena , Boshchenko, A , Rodríguez‐Zanella, Hugo , Bursi, Francesca , Đorđević-Dikić, Ana, Amor, Miguel , Haberka, Maciej , Safarova, Ayten, Nikolic, Aleksandra, Gaibazzi, Nicola , Kovačević-Preradović, Tamara , Tripepi, Giovanni Luigi , Villari, Bruno, Carerj, Scipione , Pellikka, Patricia A. , Picano, Eugenio

Mayo Clinic

ESC Heart Failure | May 23, 2026 | Volume: 13 | Issue: 4 | Pages: No page available

10.1093/eschf/xvag151 | PMID 42249823 Get It

Abstract Introduction Transthoracic echocardiography (TTE) identifies a hypercontractile phenotype (HP) in chronic coronary syndromes (CCS), characterized by elevated resting left ventricular (LV) elastance (force = systolic blood pressure/end-systolic volume). To evaluate the prognostic significance and functional correlates of HP. Methods In a prospective multicentre study, 10 677 patients with CCS underwent resting TTE to assess LV ejection fraction (EF), stroke volume, and force by quantitative volumetric echocardiography. All patients were followed for the endpoint of all-cause mortality. In a subset of 5834 patients, stress echocardiography (exercise or dobutamine) was performed for LV contractile reserve and heart rate reserve. Results Patients were stratified into Force quintiles (Q1–Q5). Patients with hypercontractile phenotype exhibited lower stroke volume at rest (Q5 = 34.8 ± 12.3 vs Q1–Q4 = 57.4 ± 19.1 mL; P &lt; .01) and higher EF at rest (Q5 = 64.8 ± 6.9% vs Q1–Q4 = 58.1 ± 8.7%, P &lt; .01). During a median follow-up of 24 months (interquartile range = 12–40 months), 509 deaths occurred. The exposure-adjusted death rate was lowest in Q3 (3.53–4.51 mmHg/mL; 1.03 per 100 person/years) and higher in Q1 (≤2.62 mmHg/mL, 2.88), Q2 (2.63–3.52 mmHg/mL, 1.86), Q4 (4.52–6.11 mmHg/mL, 1.56), and Q5 (HP, &gt;6.11 mmHg/mL; 1.88; P &lt; .0001 vs Q1 and Q3). Multivariable analysis identified HP (Q5; HR 1.531 vs Q3, 95% CI 1.116–2.099; P = .006) and EF (HR 0.963, 95% CI 0.953–0.972; P &lt; .0001) as independent predictors of death. During exercise or dobutamine stress, HP showed reduced LV contractile reserve (ΔEF: Q5 = 4.3 ± 9.4% vs Q1–Q4 = 7.0 ± 9.3%; P &lt; .001) and blunted heart rate reserve (Q5 = 1.77 ± 0.33 vs Q1–Q4 = 1.85 ± 0.39; P &lt; .01). All patients with force-based LV contractile reserve &gt;4.1 (present in 185, 3.2% of the population) survived. Conclusion Patients with CCS with HP assessed by resting TTE demonstrate higher mortality and multilayered functional impairment, including reduced LV contractile and chronotropic reserves. Hypercontractile phenotype improved the prediction of mortality by EF. A ‘stronger’ heart is, in fact, functionally and prognostically weaker.
Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant
Zent, Clive S. , Tiacci, Enrico , Kreitman, Robert J. , Tadmor, Tamar , Tallman, Martin S., Wörmann, Bernhard J., Andritsos, Leslie A. , Arons, Evgeny , Barrientos, Jacqueline C. , Broccoli, Alessandro , Call, Timothy G., Dearden, C. J., El‐Sharkawi, Dima , Fagarasanu, Andrei, Gladstone, Douglas E. , Gozzetti, A, Hampel, Paul J. , Hermel, David J. , Johnston, James B. , Juliusson, Gunnar, Kipps, T J, Lauria, Francesco, Lozanski, Gerard , Park, Jae H, Polliack, Aaron, Quest, Graeme, R., K. , Rogers, Kerry A. , Saven, Alan, Seymour, John F. , Tam, Constantine S., Troussard, Xavier, Zenz, Thorsten, Grever, Michael Rhodes, Gozzetti, Alessandro , Barrientos, Jacqueline , Blachly, James , Dietrich, Sascha , El-Sharkawi, Dima , Falini, Brunangelo , Forconi, Francesco , Gerrie, Alina S , Gozzetti, Alessandro , Hampel, Paul J , Iyengar, Sunil , Johnston, James B , Parikh, Sameer A , Robak, Tadeusz , Rogers, Kerry A , Seymour, John F , Zinzani, Pier Luigi , Zent, Clive S , Tallman, Martin S. , Wörmann, Bernhard , Banerji, Versha , Bhat, Seema A. , Blachly, James S. , Call, Timothy G. , Demeter, Judit , Falini, Brunangelo , Forconi, Francesco , Gerrie, Alina S. , Juliusson, Gunnar , Kipps, Thomas J. , Lauria, Francesco, Parikh, Sameer A. , Park, Jae H. , Polliack, Aaron, Ravandi, Farhad , Tam, Constantine S. , Troussard, Xavier , Zenz, Thorsten , Zinzani, Pier Luigi , Grever, Michael R.

Mayo Clinic

Blood | April 14, 2026 | Volume: 148 | Issue: 1 | Pages: 31-42

10.1182/blood.2025032757 | PMID 41980020 Get It

Abstract Hairy cell leukemia (HCL) and HCL variant (HCLv) are distinct, rare, and chronic splenic B-cell lymphomas/leukemias that partially overlap in clinicopathologic presentation but differ in genetic basis, prognosis, and management. HCL is caused by the BRAF-V600E kinase–activating mutation in &gt;95% of the patients, usually has excellent responses to chemotherapy with purine analogues, and is also amenable to BRAF inhibitor–based targeted treatments. In contrast, HCLv lacks BRAFV600E mutation, requires combined therapy with purine analogues in addition to rituximab, and generally shows less durable responses. Here, an international team of hematologists, experts on these rare diseases, was convened by the Hairy Cell Leukemia Foundation to update the previous guidelines (published in 2017) by providing a summary of current methods to diagnose and manage patients with HCL and HCLv as well as a prospective on newer targeted therapies to further improve outcomes.